The Business Standard's Smart Investor (SI) reports focus on in-depth analysis and timely news concerning strategic investment trends, business deals, and financial manoeuvres within the corporate world.
The Business Standard's Smart Investor (SI) reports focus on in-depth analysis and timely news concerning strategic investment trends, business deals, and financial manoeuvres within the corporate world.
All that happened in the markets today
The stock slipped 10% to Rs 11.10 levels in early morning trade on the BSE.
HDFC Life Insurance will replace Vedanta in the Nifty50 index with effect from Friday, July 31, 2020
Going forward, analysts expect a ramp up of large deals won in the previous quarters and improvement in deal wins in coming quarters to drive Tech Mahindra's revenues
Here's a list of stocks that may remain in focus today.
All that happened in the markets today
Thus far in the month of July, the Nifty IT index has outperformed the market by surging 19 per cent as against Nifty 50 index which was up 8.25 per cent during the same period
The company's decorative business segment witnessed improving business conditions in May and June
According to reports, the MAI is certain that cinema halls will be allowed to reopen for the public in the next phase of unlock
In US dollar terms, revenue grew 9.5 per cent YoY to $131.02 million. Sequentially, the numbers increased by 3.1 per cent.
The private sector lender raised Rs 15,000 crore through FPO by issuing shares at the price of Rs 12 per share
Here's a list of stocks that may remain in focus today.
According to reports, Amazon.com Inc is in talks to buy a 9.9 per cent stake in the company's retail arm.
All that happened in the markets today
ICICI Securities expects Syngene's revenues to be back on track as the company is currently operating at 90 per cent capacity.
The promoter rejected the discovered price of Rs 1,100 for the proposed voluntarily delisting of shares
Signing of new deal worth $216 million deal in July 2020, in addition to the Q1 TCV declared wins worth $259 million also boosted sentiment
June performed better than May as things began to normalise; however production levels are back to only 60-70 per cent, analysts note.
Taro Pharma has reached a settlement agreement with the US Department of Justice, Antitrust and Civil divisions to pay more than $200 million to settle the generic drug price fixing allegations
The bids for these contracts were submitted in January this year and opened in March.